Author Archives: SetLance

Meet in Italy for Life Sciences 2019

August 21st, 2019 | Posted by SetLance in News - (Comments Off)
Location: Trieste, Italy 
Date: 16-18 October 2019



29th European Congress of Clinical Microbiology and Infectious Diseases

March 7th, 2019 | Posted by SetLance in News - (Comments Off)

Date: 13th-16th April 2019

Location/Venue: Amsterdam, Netherlands


Oral presentations:

Prof. Alessandro Pini "The antimicrobial peptide SET-M33. A case of preclinical drug development"




11th Berlin Conference on Life Sciences – Novel Antimicrobials and AMR Diagnostics

February 19th, 2018 | Posted by SetLance in News - (Comments Off)

conferenzaTitle of presentation:

The development of a synthetic branched peptide for fighting multi-resistant Gram-negative bacteria.

Speaker: Alessandro Pini, 

Conference website:




Seal of excellence 2017

July 19th, 2017 | Posted by SetLance in News - (Comments Off)

immagineSeal of Excellence 2017
Certificate delivered by the European Commission, as the institution managing Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020 for the project "Non-clinical development of an antimicrobial drug to fight against resistant bacteria". The project has been presented in the area dedicated to supporting biotechnology of SMEs closing the gap from lab to market following evaluation by an international panel of independent experts. SetLance was scored as a high-quality project proposal in a highly competitive evaluation process.

27th European Congress of Clinical Microbiology and Infectious Diseases

January 27th, 2017 | Posted by SetLance in News - (Comments Off)

Date: 22-25 April 2017

Location/Venue: Vienna, Austria


Two oral presentations:

Dott. Chiara Falciani "An antimicrobial peptide to face multidrug-resistance emergency: synergies and mechanism of action underpinning efficacy".

 Dott. Alessandro Pini "The peptide SET-M33 as novel agent to neutralize and remove LPS in patients with sepsis".



We are on CORDIS

June 28th, 2016 | Posted by SetLance in News - (Comments Off)

The article ''A new hope for treating severe pneumonia'' featuring Setlance's antimicrobial peptide M33 was published on CORDIS (Community Research and Development Information Service), the European Commission’s primary public repository and portal to disseminate information on EU-funded research projects.

Read the whole article here:



PhD position financed by SetLance

October 12th, 2015 | Posted by SetLance in News - (Comments Off)

October 2015. SetLance finances a PhD position in Biochemistry and Molecular Biology, XXXI cycle of the regional doctorate "Pegasus" ( The selected student will be trained in SetLance laboratories working on projects related to the characterization and development of antimicrobial and anti-inflammatory peptides.

Publication of the BEAM Alliance’s Position Paper

September 30th, 2015 | Posted by SetLance in News - (Comments Off)

The BEAM Alliance urges European and national public authorities to take three key short term actions with immediate effect: (1) create a specific fund dedicated to small and medium biopharmas developing innovative antibacterial products, (2) enhance market incentives to increase the Return on Investment for products tackling antimicrobial resistance through the creation of a special status, (3) simplify regulatory pathways for products tackling antimicrobial resistance.

Download the BEAM Position Paper and the English Press Release


BEAM Alliance Website




3rd International Congress on Bacteriology and Infectious Diseases

September 17th, 2015 | Posted by SetLance in News - (Comments Off)

Recent developments in Bacterial Diseases, Bacteriology and Infectious Diseases.

Date:04.08.2015 – 06.08.2015
Location/Venue: Meliá Valencia, Valencia, Spain
Organisers: OMICS International

Adhesion of SetLance to BEAM Alliance

March 31st, 2015 | Posted by SetLance in News - (Comments Off)

Date: March 2015

Launch of BEAM Alliance – Biotechs of Europe innovating againts Anti-Microbial resistance


The BEAM Alliance intends to:
•Regroup European emerging biotech companies who are involved in developing innovative products to tackle antimicrobial resistance ;
•Represent them with a unique voice to propose and support policies and regulatory solutions to member-identified problems;

In order to reinforce the attractiveness of this therapeutic area, support the development of new products and accelerate market access of such new products for the European patients. The Group seeks to collaborate with the existing community of stakeholders dedicated to implementing tangible solutions to combat this serious public health issue. Our mission is to recommend incentives that warrant further consideration and action to policymakers and others to overcome these challenges and address the threat of antibacterial resistance, now and in the future.